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Abstract 
Radioligand binding and cDNA homology studies have suggested the existence of opiate receptors distinct from the recently-cloned p, S and K 
receptors. XORlS, a rat brain cDNA whose predicted translation product displays 67-72% homology with those encoded by ~1, 61 and ~1 opiate 
receptor cDNAs, was constructed from two partial cDNAs identified through cDNA homology approaches. A longer XORlL variant of this cDNA 
was also identified by polymerase chain reaction studies using genomic DNA and cDNA from brain and peripheral tissues. XORl mRNA is most 
highly expressed in hypothalamus. COS cell expression of both clones confers neither robust binding of opiate hgands nor reproducible opiate 
inhibition of forskolin-stimulated adenylate cyclase. These studies identify an orphan clone that helps to define features of the opiate receptor gene 
family, including apparent differential splicing and expression in peripheral tissues. 
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1. Introduction 
Multiple receptor sites recognizing exogenous opiate 
drugs and endogenous opioid peptides have been defined 
based on radioligand binding and pharmacological ex- 
periments [1,2]. ,u, 6 and FC opioid receptors have been the 
focus of most attention, although an E receptor has also 
been postulated (e.g. [l-6]). Recent cDNA cloning stud- 
ies have identified members of the seven transmembrane 
domain, G-protein-linked neuropeptide receptor family 
that encode prototypic members of the p, 6 and FC opioid 
receptor families [7-151. 
We now report evidence, obtained by screening cDNA 
libraries with hybridization probes derived from various 
opiate receptor sequences, that this opiate receptor gene 
subfamily contains members that differ from the ini- 
tially-cloned p, 6 and FC~ receptors [7-151. Using polym- 
erase chain reaction (PCR) and cDNA homology ap- 
proaches, we have identified several overlapping cDNAs 
that encode a translation product termed XORlS, due 
to its high homology with the initially-cloned p, 6 and IC, 
receptors [7-151. The XORl mRNA appears to display 
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splice variants altering amino acid sequences to form 
XORlL and XORlS. Long and short XORl forms are 
differentially expressed in brain regions and peripheral 
tissues, but neither manifests either robust binding of 
opiate ligands or opiate inhibition of forskolin-stimu- 
lated adenylate cyclase activity when expressed in COS 
cells, These receptors’ sequences contribute to our under- 
standing of the opiate receptor gene subfamily and its 
relation to the subfamily of neuropeptide neurotransmit- 
ter receptors. 
2. Materials and methods 
2.1. Cloning candidate rat brain opioid receptor subfamily cDNAs 
Candidate rat opioid receptor cDNAs and genomic clones were ob- 
tained using several mRNA and cDNA sources and several oligonucle- 
otide primers for PCR amplification, as described [7]. pPCR4A was a 
700 base pair (bp) pPCRI1 (InVitrogen) subclone of a partial p opiate 
receptor cDNA amplified from single stranded rat brain cDNA, as 
described [7j. The 700 bp pPCR4A insert was excised with EcoRI, 
radiolabelled by random priming, and used to isolate cDNAs from a 
size-selected rat cerebral cortex lambda ZAP cDNA library, as de- 
scribed [7j. Sequence analyses of the inserts from autoexcised plasmids 
revealed apparent partial sequences with substantial homology to other 
cloned opiate receptors, including a 2.8 kb cDNA termed RC9-1-5. A 
5’ 500 bp fragment of RC9-l-5 was isolated using HindIII, the fragment 
was radiolabeled by random priming, and used to isolate other more 
5’ cDNAs including a 3 kb cDNA, RC13-1, as described [7]. The 5’ end 
from RC 13-l and the 3’ end from RC9- l-5 were cut and ligated to form 
a fused clone termed XORlS. 
Convergent data was also obtained from PCR-based studies of rat 
genomic DNA. pOpiorph1 was a 636 bp pPCRI1 cDNA subclone 
amplified from rat genomic DNA using two rounds of polymerase 
chain reaction and primers 5’-ACGATGAA(GC)AC(IGA)GCCAC- 
CACCA-3’ [16] and 5’-CTTCAA(TC)CKiGC(TC)‘ITGGCTGAT-3 
[12], derived from p and S receptor cDNA sequences, respectively. 
All rights reserved. 
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pXORlS and pOPIORPH1 were subjected to complete sequencing of 
both strands using automated and manual methods as described [7]. 
The long form splice variant cDNA, pXORlL, was generated by fusing 
pOpiorph1 and the pXORlS. Both pXORlS and pXORlL were also 
subcloned into pcDNA1 (InVitrogen) to yield pcDNAlXORlS and 
pcDNAXOR 1 L. DNA sequences were analyzed using GCG software 
P71. 
2.2. Expression in COS cells and assessment of opiate pharmacologic 
properties 
COS cells were transfected by electroporation with 20 pug/lo’ cells of 
DcDNAIXORIL. ncDNAlXORlS. or ncDNA1 vector. as described 
i18,19]. Transfectkd cells were plated inDulbecco’s modified minimal 
essential medium (DMEM) containing 10% fetal bovine serum (FBS), 
cultured for 2-3 days, and tested for opiate receptor expression by 
radioligand binding and adenylate cyclase assays as described [7]. Radi- 
oligands included: rH]bremazocine (29.2 Ci/mmol, NEN), [‘Hlnalox- 
one (47.2 Wmmol, NEN), [‘Hldiprenorphine (29 Cilmmol, NEN), 
[‘HIDAMGO ([o-Ala2,N-Methyl-Phe4,Glyol5]enkephalin; 60 Ci/ 
mmol, Amersham), [‘H]DPDPEpCl ([o-Pen2,4’-Cl-Phe4,n-PenS]enke- 
phalin; 51 Ci/mmol, NEN), [‘HIDADLE (D-Ald,D-hAd enkephalin; 
37 Wmmol, NEN), [‘Hlethylketocyclazocine (28.5 Ci/mmol, NEN), 
[3H]etorphine (38.7 Ci/mmol, NEN), [3H]buprenorphine (13.4 Ci/ 
mmol, RBI), [‘251]B-endorphin (2,000 Ci/mmol, Amersham) and [3H]IJ- 
69,593 (57 Ci/mmol, Amersham). CAMP accumulation stimulated by 
10 PM forskolin was assessed in 24-well plate COS cell cultures prein- 
cubated for 15 min with 1 mM IBMX (3-isobutyl-l-methylxanthine) as 
described [7] (kit No. KAPHZ, Diagnostic Products, Los Angeles). 
2.3. XOR expression 
RNA was prepared from rat tissues that were rapidly dissected and 
frozen at -70°C. 2Opg of total RNA was prepared and electrophoresed 
along with molecular weight standards (BRL) and transferred to nylon 
membranes as described [20]. Blots were hybridized with the 2.8 kb 
RC9-1-5 cDNA radiolabelled with 32P by random priming in 50% 
formamide, 5 x SSC, 50 mM NaPO,, 1% SDS, 2.5 x Denhardt’s solu- 
tion, 200 pg/ml salmon sperm DNA at 42°C overnight, washed twice 
in 0.1 x SSC/O.I% SDS for 30 min at 65°C and radioactive patterns 
identified using a phosphorimaging device (Molecular Dynamics) fol- 
lowing overnight exposures. 
Reverse transcription-PCR was performed using 5 pg of total RNA 
extracted from different tissues and oligonucleotide primers 5’-ACC- 
CTGGTC’ITGCTAACA-3’ and 5’-CAGCACCAGTCGAGTGAT- 
3’, as described (Perk&Elmer RT-PCR Kit). Single-stranded cDNA 
was amplified by 35 cycles of 94°C for 1 min, 55°C for 1 min, and 92°C 
for 1 min), with separation of PCR products by 2% agarose gel electro- 
phoresis, transfer to nylon membranes, hybridization overnight with a 
“P-labeled 9-l-5 cDNA probe at 42°C as described [7], and phosphor- 
imaging. 
3. Results 
Analyses of the rat cerebral cortex cDNAs RC9-l-5 
and RC13-1 revealed an open reading frame of 367 
amino acids with 52% identity to the rat &opioid recep- 
tor cDNA [9], 54% to the rat ,u-opiate receptor [7-91, and 
52% to the rat K-opiate receptor sequence [13-151 (Figs. 
1 and 2). This sequence was confirmed by partial se- 
quencing of more than four additional distinct cDNAs 
(data not shown). The composite cDNA fused from 
RC9-1-5 and RC13-1 yielded a 3.2 kb opiate receptor 
subfamily fusion cDNA with 120 bp of apparent 5’ un- 
translated region, 2.0 kb of 3’ untranslated region includ- 
ing a polyadenylation sequence, and 1,lO 1 bp encoding 
the open reading frame. Hydrophobicity analyses re- 
vealed that the seven hydrophobic candidate transmem- 
brane regions of 20-24 amino acids contained sequences 
especially conserved with other G-linked receptors. 
Three consensus equences for N-linked glycosylation in 
the putative extracellular N-terminal domain, and serine 
and threonine residues found in possible intracellular 
domains in sequence contexts favorable for protein ki- 
nase A and C phosphorylation were also notable [2 1,221; 
(Fig. 1). 
Comparison of these sequences with those of pOPI- 
ORPHl revealed 84 additional base pairs in pOPI- 
ORPHl that are flanked by consensus sequences for 
hnRNA splicing and encode additional open reading 
frame segments (Fig. 1). The spliced segment contains an 
additional site for potential N-linked glycosylation 
(Fig. 1). 
Northern analysis of the distribution of XORl mRNA 
reveals highest levels of expression in the hypothalamus 
(Fig. 3A). At least three hybridizing mRNA species are 
observed in this brain region and in brainstem, midbrain, 
cerebral cortex, thalamus and hippocampus but not in 
striatum or cerebellum (Fig. 3A and data not shown). 
RT-PCR approaches revealed two splice variant prod- 
ucts in tested brain regions as well as in several periph- 
eral tissues uch as intestine, skeletal muscle, vas deferens 
and spleen (Fig. 3B). The ratio between XORlS and 
XORlL expression also varies among the brain regions 
and peripheral tissues examined (Fig. 3B,C). 
Transient COS cell expression of neither the XORIS 
nor XOR 1 L pcDNA 1 subclone yielded consistent bind- 
ing of any tested ligand. In 14 experiments in which 
robust binding to rat or human pOR1 cDNAs provided 
positive control data, eight of ten displayed no specific 
radioligand binding above background levels to cells ex- 
pressing XORlS and four of four displayed no specific 
binding to cells expressing XORlL. In two experiments, 
modest naloxone-displacable diprenorphine, bremazoc- 
ine, and p-endorphin binding above background values 
was noted in XOR 1 S-transfected cells (data not shown). 
However, intermittent naloxone-displacable binding of 
naloxone and j&endorphin was also observed in mock- 
transfected COS cells in several negative control experi- 
ments. Neither radiolabeled diprenorphine, bremazoc- 
ine, nor B-endorphin displayed specific binding in eight 
additional experiments; neither ethylketocyclazocine, 
naloxone, DAMGO, DPDPE, U,69,593, etorphine, bu- 
prenorphine, nor DADLE revealed specific binding in 
any experiment (more than two experiments each; data 
not shown). 
COS cells transfected with pXORlS or pXORlL 
failed to display consistent opiate-induced alterations in 
forskolin-stimulated adenylate cyclase activity. In 14 ex- 
periments in which morphine-inhibited adenylate cyclase 
activity in COS cells expressing rat or human pOR1 
cDNAs served as positive controls, eight of 10 experi- 
ments displayed no opiate-mediated inhibition of fors- 
kolin-stimulated cyclase activity in cells expressing 
XORlS and four of four experiments displayed no opi- 
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ate-mediated inhibition of forskolin-stimulated cyclase 
activity in cells expressing XORlL. In two experiments, 
bremazocine, buprenorphine, etorphine and j?-endor- 
phin did display modest naloxone-reversible inhibition 
of forskolin-stimulated cyclase activity in cells expressing 
XOR 1 S. However, intermittent naloxone-reversible 
/3-endorphin effects were also noted in some experiments 
in mock-transfected cells (data not shown). Neither bre- 
mazocine, buprenorphine, etorphine nor /I-endorphin 
altered forskolin-stimulated CAMP levels in eight addi- 
tional experiments; neither DADLE, Dynophin A, mor- 
77 
phine nor U50,488 altered CAMP levels in any experi- 
ment (more than two experiments each; data not shown). 
4. Discussion 
The sequences of the XORl S and XORl L cDNAs 
described here clearly place them within the family of 
G-protein linked, seven transmembrane domain recep- 
tors, and within the opiate receptor subfamily of receptor 
genes (Fig. 2). The distributions of the mRNAs ex- 
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Fig. 1. Amino acid sequence of the rat brain orphan opiate receptor family member predicted from the sequences of the cDNA for XORlS and 
XORlL, and comparison of the sequence to other opiate receptor family members. XORlS and XORlL were subjected to double stranded sequencing 
by automated and manual means, and the translation product open reading frame aligned with those of the rat b-opioid receptor (rDorl), rat p-opiate 
receptor (rMor1) and the rat K-opiate receptor (rKor1) using the program PILEUP. Putative transmembrane domains are indicated by boldface type 
and shading, putative sequences for N-linked glycosylation by #, the location of the 28 additional amino acids encoded by the splice variant is shown 
by the lines. The sequences have been truncated at 400 amino acids. The consensus sequence was derived by setting the minimum number of similar 
residues equal to three and giving thep, 8, and z sequences greater weight in the PILEUP program. The XORl nucleotide sequence has been deposited 
with Genbank (Accession No. L33916). 
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Fig. 2. Dendrogram depicting evolutionary relatedness of the proteins 
predicted from XORl and other G-protein-linked receptor cDNAs. 
The dendrogram was generated from the top 40 most related protein 
sequences identified by searching all available data bases using the 
computer programs Tfasta and PILEUP. Other G-protein linked recep- 
tors are also included to show family relatedness. The sequence acces- 
sion numbers are as follows: rXORlS, rXORlL, mKOR (L11065), 
rKOR (UOO442), rDOR (D16348), mDOR (L16064), rMOR (L20684), 
hMOR (L25119), mSOMR (M81831), hSOM1 (LO7833), rSOM1 
(X62314), rSOM (M93273), hSOM4 (LO7061), hSOM14 (S59504), 
rBSSOM (M96544), mSOM2 (M81832), rSOM (LO4535), hSOM2 
(M818130), bSOM (LO6613), mSOM3 (M91000), rSOM28a (X63574), 
hSOM3 (LO7062), rSOM28 (S53287), pAII (D11340), mAIIla 
(S37484), rAI1 (M86912), hC-CCKR (LO9230), hFPR1 (L10820), 
hOBP (M84605), rNMK (505189) cgRHOD (X61084), rB2AR 
(X17607). 
pressed from this gene are consistent with the possibility 
that it could encode a neurotransmitter receptor protein. 
The elucidation of the present cDNAs appear to add 
substantially to evidence for the diversity of the gene 
subfamily that contains opiate receptors. The splice var- 
iant documented for this receptor represents the first 
example of differential splicing in this receptor gene sub- 
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Fig. 3. Expression of XORl mRNA. (A) Northern analyses from a 
representative phosphorimager autoradiogram of XORl mRNA hy- 
bridization to radiolabeled RC9-1-5 cDNA in 20 pg total RNA ex- 
tracted from rat thalamus (lanes l-4), hypothalamus (lanes 68) and 
striatum (lanes 9-12). Size markers (lane 5) suggest 3.3 kb, 13.0 kb, 23.0 
kb sizes for the three hybridizing mRNA species. (B) Reverse transcrip- 
tion/polymerase chain reaction amplification products of mRNAs ex- 
tracted from various brain and peripheral tissues with XORl gene 
products detected by hybridization with a radiolabeled RC9-1-5 cDNA. 
Lane 1, cerebellum; lane 2, cerebral cortex; lane 3, striatum; lane 4, 
midbrain; lane 5, hippocampus; lane 6, brainstem; lane 7, olfactory 
bulb; lane 8, spinal cord; lane 9, thalamus; lane 10, hypothalamus; lane 
11, intestine; lane 12, skeletal muscle; lane 13, vas deferens; lane 14, 
esophagus; lane 15, liver; lane 16, kidney; lane 17, testis; lane 18, adrenal 
gland; lane 19, spleen. The top band (long form) is 591 bp and the 
bottom band (short form) is 507 bp, molecular size markers not shown. 
(C) Ratio of hybridization to XORlS to XORlL reverse transcription/ 
polymerase chain reaction products derived from mRNAs in each tis- 
sue is expressed as the ratio of radiolabeled hybridization probe recog- 
nizing the short form to that recognizing the long form, with hybridiza- 
tion, washing, and hybridization quantitation by phorphorimaging per- 
formed as described in the text. Similar results were noted in three 
replicate experiments. 
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family, and suggests an intron-exon border likely to be 
conserved in several opiate receptor subfamily genes [23]. 
Although this variant’s presence is well-documented in 
reverse transcriptase/polymerase chain reaction ap- 
proaches, none of the hybridizing bands noted in North- 
ern analyses differ in gel motility by the 84 bp predicted 
from the splice variant documented in the coding se- 
quence. Conceivably, two of these three mRNAs could 
represent products of different genes closely related to 
XORl in sequence. Alternatively, mRNA splicing and/ 
or polyadenylation site usage events in the XORl gene’s 
untranslated regions could yield the significant differ- 
ences in transcript molecular mass noted in Northern 
analyses. 
Several features of the XORl’s structure are consistent 
with specific functional implications. The size of the thud 
putative intracellular loop predicted by the XORl 
cDNA is modest, consistent with sizes of the homolo- 
gous segments in the seven transmembrane domain re- 
ceptors that do not couple to adenylate cyclase stimulat- 
ing G, proteins [24]. Although many residues lying in 
transmembrane regions are conserved, the XORl se- 
quence contain a glutamine at position 305 (Fig. 1) in- 
stead of the histidine that lies in comparable positions in 
the ~1, K and 6 opiate receptor sequences. The XORlL 
longer splice variant encodes 28 additional amino acids 
that separate a number of negatively charged residues in 
the putative third extracellular segment from each other 
(Fig. 1). 
The failure of the binding site conferred on COS cells 
expressing this cDNA to consistently recognize radiola- 
beled peptides or drugs that bind opiate receptors, and 
its inconsistent actions on adenylate cyclase suggests that 
this receptor’s natural ligands may not be opioid pep- 
tides and that it may contribute little to the brain actions 
of opiate drugs. Gene relatedness does not unfailingly 
predict agonist identity. The current data do suggest hat 
XORl receptors are derived from the same evolutionary 
precursors that contributed to the opiate receptor sub- 
family of G-linked receptor genes. 
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